Shree Surya Surgi Pharma Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 16-06-2024
- Paid Up Capital ₹ 0.23 M
as on 16-06-2024
- Company Age 13 years 9 months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.00 M
as on 16-06-2024
- Revenue 4.51%
FY 2023
- Profit 8.29%
FY 2023
- Ebitda -34.85%
FY 2023
- Net Worth 1.09%
FY 2023
- Total Assets -27.83%
FY 2023
About Shree Surya Surgi Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.23 M.
The Corporate currently has active open charges totaling ₹9.00 M.
Kishor Bagde, Ratnakar Tukaram, and Vikrant Suryawanshi serve as directors at the Company.
- CIN/LLPIN
U33111MH2010PTC211320
- Company No.
211320
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Dec 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Shree Surya Surgi Pharma Private Limited offer?
Shree Surya Surgi Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Injectable Products, Anti Infective Drugs & Medicines, Remdesivir Injection, Anti Cancer Medicines, Arimidex Tablets, Cardiovascular Drugs & Medication, Cardiac Drugs, Oncology Drug.
Who are the key members and board of directors at Shree Surya Surgi Pharma?
Board Members(3)
Financial Performance and Corporate Structure Insights of Shree Surya Surgi Pharma.
Shree Surya Surgi Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.51% increase. The company also saw a slight improvement in profitability, with a 8.29% increase in profit. The company's net worth moved up by a moderate rise of 1.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shree Surya Surgi Pharma?
In 2023, Shree Surya Surgi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shreesurya Pharma Private Limited
Active
8 years 6 months Ratnakar Tukaram and Vikrant Suryawanshi are mutual person
Nexreet Ceutics Private Limited
Active 2 years 11 months Ratnakar Tukaram and Vikrant Suryawanshi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Jul 2022 | ₹5.00 M | Open |
Others Creation Date: 10 May 2012 | ₹4.00 M | Open |
How Many Employees Work at Shree Surya Surgi Pharma?
Unlock and access historical data on people associated with Shree Surya Surgi Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Feb 02, 2022, Shree Surya Surgi Pharma has raised a total of ₹ 1.66 M, with the most recent deal valued at ₹ 0.23 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
